MedTrace Logo

miRNA in Septic Acute Kidney Injury

NCT06498336 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2024-07-12

No results posted yet for this study

Summary

Acute kidney injury is a common and serious complication of sepsis and septic shock, which may be associated with a worse outcome of the patient's condition. The exact pathophysiological mechanism of septic acute kidney injury remains a challenge. One of the possible causes appears to be endothelial dysfunction and mitochondrial damage of renal tubular cells. The aim of this study is to identify specific microRNAs associated with these pathophysiological events in sepsis and septic acute kidney injury. And to establish a new potential diagnostic or therapeutic target for the prevention or treatment of septic acute kidney injury.

Conditions

Interventions

DIAGNOSTIC_TEST

Laboratory examination to determine the presence of sepsis

Standard laboratory biochemical methods will be used to determine sepsis diagnosis accord-ing to SEPSIS 3 (1). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.

DIAGNOSTIC_TEST

Laboratory examination to determine the presence of sepsis and acute kidney injury

Standard laboratory biochemical methods will be used to determine sepsis diagnosis according to SEPSIS 3 and acute kidney injury according to Guidelines Kidney Disease Improving Global Outcomes (KDIGO) 2012 (2). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.

DIAGNOSTIC_TEST

Laboratory examination to determine miRNA and biochemical parameters

Laboratory examination will be performed to determine miRNA and biochemical parameters.

Sponsors & Collaborators

  • University Hospital Olomouc

    collaborator OTHER

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Naděžda Petejová, Assoc.Prof.,MD,PhD,MSc · University Hospital Ostrava

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-02
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06498336 on ClinicalTrials.gov